文献速递甲状腺疾病

索拉非尼治疗肝细胞癌患者中甲状腺激素水平的变化

Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

这项前瞻性队列研究纳入2009至2016年间57例接受索拉非尼治疗的肝细胞癌连续患者,每6周监测促甲状腺激素(TSH)和游离甲状腺素(FT4),并在治疗前、6周及治疗结束时行全面甲状腺功能检查。结果显示4例(7%)发生甲状腺炎,另30%患者TSH或FT4升高超出正常范围;t0至t6平均TSH由1.28升至1.57 mU/L(P<0.001),平均FT4由18.4升至21.2 pmol/L(P<0.001),同时T3/rT3比值及(T3/甲状腺素)×100比值下降。体外实验提示索拉非尼经MCT8(较小程度经MCT10)抑制细胞T3摄取。

要点

  • 57例肝细胞癌患者接受索拉非尼治疗,4例(7%)发生甲状腺炎,另30%患者TSH或FT4升高超出正常范围。
  • 治疗前至6周,平均TSH由1.28升至1.57 mU/L(P<0.001),平均FT4由18.4升至21.2 pmol/L(P<0.001)。
  • 同期血清T3/rT3比值及(T3/甲状腺素)×100比值下降。

核心结论

  • 体内数据提示索拉非尼在多个层面影响甲状腺功能检查。
  • 体外实验提示索拉非尼抑制MCT8和MCT10介导的T3转运进入细胞可能发挥作用。

研究设计与样本

  • 前瞻性队列研究,2009年至2016年在一家三级转诊中心纳入57例接受索拉非尼治疗的肝细胞癌连续患者。
  • 每6周测量TSH和FT4,并在治疗前(t0)、6周(t6)及治疗结束时行全面甲状腺功能检查。
  • 在转染的COS1细胞中检测索拉非尼对单羧酸转运蛋白(MCT)8或MCT10介导的甲状腺激素转运的影响。

主要发现

  • 4例患者(7%)发生甲状腺炎。
  • 其他患者中30%出现TSH或FT4升高超出正常范围。
  • t0至t6,平均TSH由1.28升至1.57 mU/L(P<0.001),平均FT4由18.4升至21.2 pmol/L(P<0.001)。
  • 同期血清三碘甲状腺原氨酸(T3)/反三碘甲状腺原氨酸比值及(T3/甲状腺素)×100比值下降。
  • 索拉非尼降低MCT8介导的细胞T3摄取,对MCT10介导的摄取降低程度较小。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The pathogenesis of tyrosine kinase inhibitor-induced thyroid hormone (TH) alterations are still a matter of debate. OBJECTIVE: The objective of this study was to determine the effects of sorafenib on TH levels in patients with hepatocellular carcinoma (HCC) and to evaluate possible mechanisms. DESIGN: We performed a prospective cohort study between 2009 and 2016. SETTING: This study was conducted at a tertiary referral center. PATIENTS: This study included 57 consecutive patients with HCC who were treated with sorafenib. MAIN OUTCOME MEASURE: Thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels were measured every 6 weeks, and extensive thyroid function tests (TFTs) were measured before treatment (t0), after 6 weeks (t6), and at the end of therapy. The effect of sorafenib on TH transport by monocarboxylate transporter (MCT)8 or MCT10 was tested in transfected COS1 cells. RESULTS: Four patients (7%) developed thyroiditis. Among the other patients, 30% had elevation of TSH or FT4 above the normal range. Overall, between t0 and t6, mean TSH increased from 1.28 to 1.57 mU/L (P < 0.001) and mean FT4 from 18.4 to 21.2 pmol/L (P < 0.001). Simultaneously, the serum triiodothyronine (T3)/reverse triiodothyronine ratio and the (T3/thyroxine) ×100 ratio decreased. Sorafenib decreased cellular T3 uptake by MCT8 and to a lesser extent by MCT10. CONCLUSIONS: These in vivo data suggest that sorafenib affects TFTs on multiple levels. Our in vitro experiments suggest a possible role of sorafenib-induced inhibition of T3 transport into the cell by MCT8 and MCT10.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Beukhof CM, van Doorn L, Visser TJ, et al. Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma. J Clin Endocrinol Metab. 2017. PMID: 28575418. doi:10.1210/jc.2016-4025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。